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ABSTRACT - PURPOSE: In order to enhance cellular uptake and to facilitate transdermal delivery of DNA 
vaccine, polyamidoamine (PAMAM) dendrimers conjugated with HIV transactivator of transcription (TAT) was 
developed. METHODS: First, the plasmid DNA (pIRES-H5/GFP) nanoparticle was formulated using PAMAM 
dendrimer and TAT peptide and then characterized for surface charge, particle size, DNA encapsulation and 
protection of the pIRES-H5/GFP DNA plasmid to enzymatic digestion. Subsequently, the potency of the TAT-
conjugated dendrimer for gene delivery was evaluated through in vitro transfection into Vero cells followed by 
gene expression analysis including western blotting, fluorescent microscopy and PCR. The effect of the TAT 
peptide on cellular uptake of DNA vaccine was studied by qRT-PCR and flow cytometry. Finally, the ability of 
TAT-conjugated PAMAM dendrimer for transdermal delivery of the DNA plasmid was assessed through 
artificial membranes followed by qRT-PCR and flow cytometry. RESULTS: TAT-conjugated PAMAM 
dendrimer showed the ability to form a compact and nanometre-sized polyplexes with the plasmid DNA, having 
the size range of 105 to 115 nm and a positive charge of +42 to +45 mV over the N/P ratio of 6:1(+/-).  In vitro 
transfection analysis into Vero cells confirms the high potency of TAT-conjugated PAMAM dendrimer to 
enhance the cellular uptake of DNA vaccine.  The permeability value assay through artificial membranes reveals 
that TAT-conjugated PAMAM has more capacity for transdermal delivery of the DNA compared to unmodified 
PAMAM dendrimer (P<0.05). CONCLUSIONS: The findings of this study suggest that TAT-conjugated 
PAMAM dendrimer is a promising non-viral vector for transdermal use. 
 
This article is open to POST-PUBLICATION REVIEW. Registered readers (see “For 
Readers”) may comment by clicking on ABSTRACT on the issue’s contents page. 
_______________________________________________________________________ 
 
INTRODUCTION 
 
Over the past few years, numerous studies have 
suggested that DNA vaccines are the simple and safe 
approach to induce both humoral and cellular 
immune responses against multiple antigens or 
pathogens. However, for efficient delivery of DNA 
vaccines into the eukaryotic cells, development of 
suitable carrier systems for gene delivery is desired. 
In contrast to viral vectors, non-viral delivery 
systems including lipid-based vectors, 
polysaccharides, cationic polymers and cell-
penetrating peptides offer several advantages, as 
they are safe, simple, and easy to manufacture as 
well as flexible in DNA loading. In addition, they 
are non-immunogenic and thus are able to prevent 
DNA degradation (1-3). Dendrimers are 
monodisperse three-dimensional and hyperbranched 
molecules that have received extensive interest as 
non-viral vectors for gene delivery because they are 
capable of forming a compact complex with genetic 
materials and protect them from degradation (4, 5). 
Among the different types of dendrimers, the 
polyamidoamine (PAMAM) dendrimers have the 
ability to efficiently transfect DNA into the different 
types of cell in vitro and the inherent ability to 
transfect the genes in vivo (6).  
The efficiency of PAMAM dendrimer in DNA 
delivery, has been shown to be improved upon by 
partial PEGlation, acetylation, alkylation (4, 7), and 
also by surface modification with some positively 
charged amino acid such as arginine and lysine (8, 
9). 
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Studies have also shown that a combination of 
modified TAT peptide and cationic lipids or 
polycations dramatically enhance transfection 
efficiency across a range of cell lines (10).   
Cell-penetrating peptides (CPPs) are defined as 
short sequences of amino acid residues which are 
able to cross easily the plasma membrane. 
Generally, CPPs are classified into two categories: 
lysine-rich peptides like the amphipathic MPG 
peptide or transportan and arginine-rich peptides like 
homeodomain of antennapedia or trans-activating 
transcriptional activators (TAT) (11). The 
application of CPP as proven in vaccine studies 
involves the presentation of target tumor-associated 
antigen into APCs, which are used as a non-viral 
delivery system in DNA vaccine. (12). 
The PAMAM dendrimers have been used as a 
carrier for transdermal delivery of drugs (13, 14). 
However, the application for transdermal delivery of 
DNA plasmids has not been investigated. Moreover, 
the skin layer is getting increasing attention as an 
alternate route of immunization as it is identified to 
be highly tenanted with professional antigen-
presenting cells, which are important in effective 
induction of immune responses. Several approaches 
have been reported for delivering DNA vaccines to 
the skin including; intradermal injection and 
physical disruption methods such as jet injection, 
electroporation, gene gun or microdermabrasion 
(15). Most of these methods need complex 
vaccination equipment and high cost of acquisition, 
which limit their widespread application. Hence, 
development of a low-cost and convenient method 
for delivering of DNA vaccine through the skin is 
required.  In the present study, we present a carrier 
system based on the G5-PAMAM dendrimers 
conjugated with TAT for transdermal delivery of a 
DNA vaccine encoding avian influenza virus (AIV) 
H5 protein.  
 
METHODS  
 
Formulation of TAT-conjugated PAMAM 
dendrimer 
PAMAM dendrimer (Sigma, USA) (0.343 µmol) 
was reacted with sulfo-LC-SMPT (Sigma, USA) 
(6.63 µmol) in phosphate-buffered sulfate (PBS) for 
12 h at 4 °C. TAT peptide (13.30 µmol) in PBS/50 
mM was then added to the intermediate, and the 
reaction was maintained at a room temperature for 
24 h. Finally, the reaction mixture was purified on a 
G25 column as previously described (16).  The 
TAT-PAMAM complex was characterized by using 
1H NMR (500 MHz NMR). 1H NMR spectra were 
recorded at 26 °C on a 500 MHz Varian INOVA 
NMR spectrometer operating at a proton NMR 
frequency of 499.887 MHz. 
 
Construction of DNA plasmid 
The pIRES-H5/GFP encoding AIV H5 and green 
fluorescence protein (GFP) was constructed by 
cloning the full length of H5 fragment of AIV strain 
A/Ck/Malaysia/5858/04 (H5N1) at multiple cloning 
sites of the CMV promoter upstream of the GFP-
encoding gene (17). The plasmid DNA (pDNA) was 
transformed and propagated into E. coli TOP10 
competent cells. And purification of pDNA was 
carried out using QIAprep Spin Miniprep Kit 
according to the manufacturer’s instructions.  
 
Preparation of pDNA/dendrimer nanoparticles 
DNA-TAT/PAMAM nanoparticles were prepared 
by mixing 2 μg of pIERS-H5/GFP with PAMAM 
and TAT-PAMAM at a different ratio from 1:1 to 
10:1 in serum-free DMEM medium followed by 20 
min incubation at room temperature. 
 
Characterization of self-assembled pDNA 
Covering of the pDNA by the dendrimer was tested 
on 1% agarose gel (Promega, USA). For this 
purpose, 200 ng of DNA was loaded on 1% gel at 80 
V for 40 min. It was then stained with ethidium 
bromide for 15 min. DNA complexation was 
considered successful when the migration of the 
DNA band was retarded on the gel. To confirm 
physical covering of the plasmid, the pDNA-
TAT/PAMAM complex was treated with DNase I (1 
U/μg of DNA) at 37°C for 30 min. The reaction was 
stopped with 0.25 M EDTA solution (0.25 M), and 
the polyplexes were then disassembled by adding 
11.4 μL SDS (15%) followed by 10 min incubation 
at RT and the addition of 20 μL of heparin (7%). 
After 1 hour incubation at RT, the samples were 
loaded on 1% agarose gel. 
 
Particle size and zeta-potential analysis 
A ten-fold dilution of the samples in pure water was 
prepared and then subjected to a photon correlation 
spectroscopy (Zetasizer 3000; Malvern Instruments, 
Malvern, UK). The average of three measurements 
was used and expressed as Z-average diameter (nm) 
±S.D and zeta-potential (mV) ±S.D. 
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Cytotoxic assay against eukaryotic cells 
Cytotoxicity of the dendrimers and pDNA-
dendrimer complex against Vero cells was assessed 
based on the MTT cell proliferation assay. Vero 
cells in Dulbecco’s Modified Eagles Medium 
(DMEM) and 10% FBS were seeded into 96-well 
microplates at the density of 104 cells/well and then 
incubated at 37ºC in a CO2 incubator for 24 h. The 
samples were serially diluted ten-fold in DMEM 
medium and added to the cells and the plates were 
incubated at 37ºC for another 72 h.  MTT assay 
reagent (20 μl, 5 mg/ml) was added to each well and 
after 4 h incubation, formazan crystals were 
dissolved in 100 μL DMSO (Sigma, USA) and 
finally, the absorbance was determined at 570 nm by 
a microplate reader (Biotech, Inc, USA). Cell 
viability was calculated as the percentage of 
absorbent compared to control. The 50% inhibitory 
concentration (IC50) value, defined as the amount of 
the complex that inhibits 50% of cell growth, which 
was calculated from the concentration–response 
curves. 
 
In vitro expression study 
Vero cells were seeded at a density of 5x104 
cells/well, in a 6-well plate in DMEM medium 
supplemented with 10% FBS and grown at 37oC in a 
CO2 incubator to reach 70–80% confluence prior to 
transfection. The medium was exchanged with a 
fresh serum-free medium, and the cells were treated 
with polyplex for 4 h. The medium was then 
exchanged with serum-containing DMEM, and the 
cells were incubated at 37ºC for 24 to 48 h. Finally, 
expression of the reporter protein, GFP and the 
transgene AIV H5 was evaluated as follow. 
 
Expression analysis of the reporter green 
fluorescence protein (GFP) 
In vitro expression of the GFP was measured and 
photographed at the magnification of ×20 using a 
fluorescence microscope (Zeiss, Germany), 24 and 
48 h post-transfection. Quantification of the green 
fluorescence was assessed by flow cytometry. The 
cells were washed in PBS, dissociated with 200 µl of 
0.25% trypsin and re-suspended in a total volume of 
1 ml following the addition of 800 µl PBS 
containing 10% FBS. The cells were used 
immediately subjected to the Guava easyCyte™ 
Flow Cytometry (Merck Millipore, Germany). 
 
 
 
Expression analysis of the AIV H5 gene 
Transcriptional expression of the H5 gene was 
assessed by reverse transcription-polymerase chain 
reaction (RT-PCR). Total RNA was extracted from 
the Vero cells using Direct-Zol RNA MiniPrep kit 
(Zymo Research, USA) based on the manufacturer 
protocol with some modifications. Briefly, 
transfected cells were lysed by Trizol reagent 
(Invitrogen, USA) and centrifuged at 12,000 ×g for 
1 min. One volume ethanol was mixed with one 
volume of the sample.  The mixture was loaded into 
a Zymo-spin IIC column tube and centrifuged at 
12,000 x g for 1 min. The samples were washed with 
Directzol RNA prewash solution and RNA wash 
buffer and dissolved in RNase-free water. The purity 
of the extracted RNAs was evaluated by measuring 
OD260/OD280 ratio. The extracted RNAs were 
treated with DNase I prior to RT-PCR. To confirm 
DNA removal from the samples, the reaction 
mixtures were tested by PCR using specific primers 
for the H5 genes. DNA-free samples were processed 
to RT-PCR using a pair of H5 specific primers, ie, 
5′ -
ATTGGCGGCCGCACCATGGAGAAAATAGTG
C-3′ and 5′-
AGCTCTCGAGTTACTTGTACAGCTCGTCCAT
G-3′. RT-PCR was carried out using the Access One 
Step RT-PCR system kit (Promega, USA). The 
reactions were performed in 25 µl volume in a 
Gradient Thermal Cycler (BioRad, USA). Following 
a reverse transcription step at 45°C for 45 min and 
then denaturation at 94°C for 3 min, the samples 
were subjected to 35 cycles of 40 s at 94°C; 1 min at 
55°C ; 2 min at 68°C ; and a final elongation step at 
68°C for 10 min. The reaction products were 
analyzed on 1% agarose gel. 
Quantitative real-time reverse transcriptase PCR 
(qRT-PCR) assay based on a Taqman probe was 
developed for quantification of H5 RNA in the 
transfected Vero cells. Total RNA was extracted 
from transfected Vero cells using Direct-Zol RNA 
MiniPrep kit as described above. The RNAs were 
transcribed into complementary DNA (cDNA) using 
high capacity RNA to cDNA Kit (Applied 
Biosystem, USA) according to the manufacturer’s 
instructions. The qRT-PCR was carried out using 
MyTaq TM HS mix kit (Bioline, USA) and specific 
primers, 5´-GAGTGTTCATTTTGTCAATG-3´ and 
3´-GGTAGATGGTAGGTATGG-5´ and probe, 
(6FAM) ACCACCATAGCAATGAG to H5. A 
standard curve was generated from ten-fold serial 
dilutions of the recombinant plasmid DNA. Data 
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was analyzed using CFX manager version 3.1 
software (Bio-Rad, USA).   
Expression of the H5 protein was also studied by 
western blotting. The transfected cells were 
harvested; washed with 1× PBS and then subjected 
to western blot analysis using mouse monoclonal 
antibody to influenza A virus as primary antibody 
and goat polyclonal antibody to mouse IgG 
conjugated to alkaline phosphatase (Abcam, USA) 
as secondary antibody. 
 
Transcellular permeability assay 
The artificial membrane, Pion Skin PAMPA (Pion, 
USA), was used as an in vitro model for passive 
transcellular permeability assay. An artificial 
membrane immobilized on a filter was placed 
between a donor and acceptor compartments.  At the 
start of the test, the donor compartment was fixed on 
the 96 well plate, including Vero cells as the 
acceptor compartment. Then, DNA-dendrimer 
complex or TAT-conjugated dendrimer polyplex in 
50µl PBS was introduced into the donor 
compartment. Following the permeation period, the 
transcriptional expression of the H5 and GFP genes 
was evaluated in the transfected Vero cells. 
 
STATISTICAL ANALYSIS 
 
The mean values of results statistically were 
analysed by one-way analysis of variance (one-way 
ANOVA) to determine the differences between 
treatment means at the 5% (P<0.05) significance 
level. Data was statistically analyzed using the 
Minitab software (Minitab, USA). 
RESULTS 
 
Synthesis and characterization of TAT-PAMAM 
complex 
TAT-conjugated PAMAM dendrimers were 
synthesis by introducing TAT residues 
(CGRKKRRQRRRPPQ) into PAMAM dendrimer 
as shown in Figure 1. 
Effective conjugation of the TAT residue was 
indicated by proton nuclear magnetic resonance 
(1H-NMR) spectroscopy (Figure 2) as follow: 1H 
NMR of PAMAM dendrimer: δ 2.44 (–
NCH2CH2CO– of PAMAM unit), 2.63 (–
CONHCH2CH2N– of PAMAM  unit and –
NCH2CH2N– of PAMAM unit), 2.72 (–
CONHCH2CH2NH2 of PAMAM unit), 2.83 (–
NCH2CH2CO– of PAMAM unit), 3.25 (–
CONHCH2CH2N– of PAMAM unit). Figure 3 
represents the respective 1HNMR spectra of the 
final chemical structure of the synthesized TAT- 
PAMAM dendrimer. The weak peaks at ?4.3–4.5 
are from the protons of -NH-CH (CH2)-CO- in 
TAT. The peaks of ? 2.7- 2.8 and ? 1.3-1.7  belong 
to the protons of -CH2-NH-NH-NH2 and -CH2-
CH2-CH2-NH-, respectively,  in arginine. In 
addition, the peaks at ? 6.5–7.5 are from the amines 
of TAT peptide sequence. 
The average number of TAT peptide 
conjugated on the surface of PAMAM was 
calculated according to the peak area ratio of 
dendrimer protons and peptide protons. An average 
number of 3 TAT peptides were modified on each 
dendrimer. 
 
 
Figure 1. Preparation of TAT- conjugated G5 PAMAM dendrimer 
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Figure 2. 1H NMR spectra of PAMAM G5 dendrimer. 1H NMR (500 MHz, δ): 2.44 (–NCH2CH2CO– of PAMAM unit H), 
2.63 (–CONHCH2CH2N– of PAMAM unit H and –NCH2CH2N– of PAMAM unit H), 2.72 (–CONHCH2CH2NH2 of 
PAMAM unit H), 2.83 (–NCH2CH2CO– of PAMAM unit H), 3.25 (–CONHCH2CH2N– of PAMAM unit H). 
 
 
TAT in  -CO-)2CH (CH-NH-4.5 (–4.3MHz, δ):  NMR (500 H1PAMAM.  conjugated-TATR spectra of H NM1 3. Figure
H), 2.7- 2.8 (-CH2-NH-NH-NH2 of arginine H), 1.3-1.7 (-CH2-CH2-CH2-NH- of arginine H), 6.5–7.5 (amines of TAT 
peptide sequence H). 
 
Preparation and characterization of pDNA self-
assembled polyplex 
The DNA plasmid pIRES-H5/GFP was designed to 
express AIV H5 and GFP proteins. The TAT-
PAMAM/DNA polyplexes were prepared at 
different N/P ratio of 1:1 to 10:1 (+/-). The 
formation of the nanoparticle complexes was 
assessed by examining the retardation in the 
migration of the plasmid DNA during agarose gel 
electrophoresis (Figure 4). At N/P ratios of 6:1 and 
above, the complexes did not migrate in the electric 
field indicating a successful covering of the pDNA 
by TAT-PAMAM. Digestion test using DNase I 
was carried out which revealed the protection 
capacity of the TAT-PAMAM polymer against 
enzymatic digestion. As shown in Figure 5, at N/P 
ratios of 6:1 and above TAT- PAMAM completely 
protected the plasmid DNA against DNase I. 
 
Particle size and zeta-potential analysis  
The zeta-potential measurement revealed a slight 
increase  in  the surface charge of the pDNA-
PAMAM and TAT-PAMAM/DNA polyplexes 
when the N/P ratio increased from 1:1 to 6:1 (+/–) 
and then maintained a constant at +32 to +33 mV 
for pDNA-PAMAM and +42 to +45 mV for TAT-
PAMAM/DNA polyplexes (Figure 6A). As shown 
in Figure 6B, the particle size increased at the 
initial stage because the dendrimers were 
distributed at the interface of DNA and the positive 
charges were insufficient to condense DNA. 
However, with the continuous addition of PAMAM 
and TAT-PAMAM, compact and stable complexes 
of about 103-115 nm and 105-115 nm were 
produced.  
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Figure 4. Agarose gel electrophoresis retardation assay. Lane 1: Plasmid DNA only; lane 2 to 11: N/P ratio of TAT- 
PAMAM /DNA of 1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1 and 10:1, respectively. The polyplexes did not migrate at N/P 
ratio of 6:1 and above indicating the DNA has formed a complete complex and unable to migrate during agarose gel. 
 
 
  
Figure 5. DNase I protection assay. Lane 1: naked plasmid DNA only, Lane 2: naked DNA treated with DNase I as a 
positive control. Lanes 3 to 12: nanoparticle complexes at N/P ratios of 1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1 and 10:1, 
respectively. At N/P ratios of 6:1 and above TAT-PAMAM dendrimer completely protected the pDNA.  
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Figure 6. (A) Zeta-potential (mV) of TAT-PAMAM-DNA and PAMAM-DNA polyplexes at different N/P ratios. (B) 
Particle size (nm) of TAT-PAMAM-DNA and PAMAM-DNA polyplexes at different N/P ratios. 
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Cytotoxic assay of PAMAM complexes 
Cytotoxicity of PAMAM, TAT-PAMAM and 
pDNA-TAT/PAMAM complexes were tested 
against Vero cells by measuring IC50 value at 72h 
post-treatment. Free PAMAM dendrimer and TAT-
conjugated dendrimer showed IC50 values of 91.2 
and 141.2 µg/ml, respectively, whereas pDNA-
TAT/PAMAM polyplex showed 50% cytotoxicity at 
the concentration of 177.82 µg/ml (Figure 7). 
 
In vitro transfection and expression analysis 
TAT-conjugated PAMAM dendrimer was tested for 
gene delivery in vitro. Vero cells were transfected 
with the pDNA-TAT/PAMAM complex and the 
expression of the reporter protein and H5 transgene 
was then assessed by immunofluorescence, RT-PCR 
and western blotting, 24 to 48 hours post-
transfection. 
Fluorescence analysis showed significant 
expression of GFP in the cells transfected with 
pDNA-dendrimer polyplex compared with naked 
DNA 48 h post-transfection (Figure 8). 
Transcriptional analysis revealed H5 expression in 
the cells transfected with pDNA-dendrimer (Figure 
9A) however, no detectable expression was observed 
in the cells transfected with the naked DNA plasmid. 
Western blotting also showed a successful 
expression of the H5 protein in pDNA/dendrimer- 
transfected Vero cells, as shown in Figure 9B.
 
  
 
  
Figure 7. MTT assay. ■PAMAM dendrimer; ▲TAT conjugated PAMAM; ●TAT conjugated PAMAM dendriplex. 
Relative cell viability was calculated as 100 X [(A570 of polymer-treated cells/A570 of blank)/ (A570 of control cells X 
A570 of blank)]. Each data point represents the mean ± standard deviation (n=6). 
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Figure 8. Expression analysis of GFP protein in Vero cells by fluorescence microscopy 48 h post-transfection. (A) pDNA-
TAT/PAMAM, (B) naked DNA, (C) Non- transfected cells. Higher GFP expression was detected in cells transfected with 
TAT-conjugated PAMAM-DNA complex compared to naked DNA. 
 
   
Figure 9. Expression analysis of the H5 gene expression in Vero cells by (A) RT-PCR:  M: GeneRulerTM DNA ladder Kit 
(Fermentas, Canada), The size of H5 gene was about 1707 bp as expected and (B) Western blotting: Arrows indicate H5 
protein (63 kDa). The detected expression of H5 as gene/protein showing successfully transcriptional expression of the H5 
gene verified the ability of TAT-conjugated PAMAM to deliver the pDNA into the cells. 
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Flow cytometry assay (Figure 10A and B and 
C) revealed significantly higher expression level of 
the reporter protein in the cells transfected with 
pDNA-PAMAM and pDNA-TAT/PAMAM 
nanoparticles when compared to the controls 
transfected with the naked plasmid DNA. The 
expression level was found to be of about 31% and 
42% for the PAMAM and TAT/PAMAM 
nanoparticles, respectively, while it was just about 
1.5% for the naked DNA (Figure 10D). 
Significantly (P<0.05), higher expression of H5 gene 
was also detected in the cells transfected with 
pDNA-dendrimer nanoparticles in comparing it with 
the naked DNA (Figure 11). 
 Figure 10. Quantitative expression analysis of the GFP in Vero cells transfected with: (A) naked DNA, (B) pDNA-
PAMAM and (C) pDNA-TAT/PAMAM using flow cytometry. (D): GFP expression analysis results from three 
experiments. The study of the GFP expression revealed underlying significant differences (P<0.05) in gene expression using 
different delivery systems including PAMAM dendrimer (31%) and TAT-conjugated PAMAM dendrimer (42%). 
Significant results indicated by symbol (*).  
 
 
 Figure 11. Quantitative expression analysis of AIV H5 gene in transfected Vero cells by qPCR. Significantly (P<0.05) 
higher expression of H5 gene revealed the enhanced transfection efficiency where PAMAM was modified with TAT 
peptide. Significant results indicated by symbol (*).  
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Transfection through artificial membrane 
The permeability value of DNA plasmid using 
PAMAM- and TAT/PAMAM-based delivery 
systems were tested on the artificial membrane, Pion 
Skin PAMPA. Following the permeation period, 
quantitative expression analysis showed the 
expression of the H5 gene in the Vero cells when 
PAMAM and/or TAT-conjugated PAMAM was 
used as a carrier for transferring the pDNA through 
the artificial membrane (Figure 12). In comparison 
with the native PAMAM dendrimer, significantly 
(P<0.05) higher H5 expression was detected when 
TAT-conjugated PAMAM dendrimer was applied 
for gene delivery. No expression was detected in the 
naked DNA group. 
The same results were observed in the GFP 
expression. And no expression was detected in the 
naked DNA group cells. However, an average 
expression of about 30% and 42% was detected 
when PAMAM or TAT/PAMAM dendrimers were 
used, respectively (Figure 13).  
  
  
Figure 12. Quantitative expression analysis of AIV H5 gene in Vero cells transfected with naked DNA, pDNA-PAMAM 
and pDNA-TAT/PAMAM through the artificial membrane, Pion Skin PAMPA. Control is non-transfected cells. The results 
showed that modified PAMAM with TAT peptide has more capability in the transition of pDNA through the artificial 
membrane system as higher expression (P<0.05) of H5 was observed from delivery system of TAT-conjugated PAMAM. 
Significant results indicated by symbol (*). 
 
 Figure 13. Quantification of the expression analysis of the GFP gene in the transfected Vero cells through the artificial 
membrane, Pion Skin PAMPA using flow cytometry. A: the GFP expression in the transfected Vero cells using the 
PAMAM dendrimer; B: the GFP expression in the transfected Vero cells using the TAT-conjugated PAMAM dendrimer; C: 
compiled results  of the GFP expression study in the transfected cells using different delivery systems including naked DNA 
(2), PAMAM dendrimer (3) and TAT-conjugated PAMAM dendrimer (4). Significant results indicated by symbol (*).  
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DISCUSSION 
 
DNA-based vaccines have emerged as an attractive 
technology in vaccine development, although one of 
the key challenges is poor immunogenicity primarily 
due to poor tissue distribution and expressions of the 
transgene or degradation by serum nucleases (18). 
Hence, various carriers such as cationic liposomes, 
polysaccharides and cationic polymers (i.e. 
polyethyleneimine, dendrimers, and chitosan) have 
been used for enhancing the uptake of DNA vaccine 
and eventually its ability to induce immune 
responses (3, 19). The high level of control possible 
over the architectural design of dendrimers 
noticeably makes them as a unique carrier in drug 
delivery systems. Although dendrimers have been 
significantly investigated over the last decades for 
transdermal drug delivery, their application as an 
appropriate delivery system for transdermal DNA 
delivery has not been explored. Therefore, the 
present study was conducted to develop PAMAM-
based nanoparticles for transdermal gene delivery. 
The PAMAM dendrimer system was modified by 
conjugating HIV transactivator of transcription 
(TAT) as cell penetrating peptide to enhance the 
uptake of the constructed DNA plasmid pIRES-
H5/GFP by the cells. Cell-penetrating peptides 
(CPPs) are highly cationic peptides usually rich in 
arginine and lysine amino acids and have the ability 
to translocate quickly into almost any live cells (20). 
The interaction between TAT-PAMAM and the 
recombinant DNA plasmid was analyzed through 
the agarose gel retardation. The N/P ratios 
corresponding to complete retardation of DNA at 6:1 
and above were able to provide complete 
neutralization of the DNA negative charges. DNase I 
treatment confirmed physical covering of the DNA 
plasmid by the TAT-PAMAM dendrimer. Size and 
zeta-potential measurements showed that PAMAM 
and TAT-PAMAM form compact nanometre-sized 
polyplexes with pDNA. Polyplexes with the size of 
100–200 nm are thought to be suitable for an 
efficient gene delivery. Additionally, TAT peptide 
conjugated to PAMAM dendrimer did not affect the 
size of the polyplex significantly. The TAT-
PAMAM polyplexes showed about 10 mV higher 
zeta-potential values than PAMAM polyplexes. This 
is thought to be due to the fact that TAT-conjugated 
dendrimers have higher charge densities and 
therefore can form polyplexes with positive charges 
which are considered to be important for their 
adsorption to negatively charged cellular membranes 
followed by cellular uptake through internalization 
mechanisms. Nanoparticles with a zeta-potential 
above (+/-) 30 mV have been shown to be stable in 
suspension, as the surface charge prevents 
aggregation of the particles (21).  
From agarose gel retardation and size and zeta-
potential measurements, the N/P ratio of 6:1 equal to 
the concentration of 60µg/ml of TAT-conjugated 
dendrimer was found to be sufficient for complete 
assembly of the DNA plasmid.  
In vitro transfection and transient gene 
expression study in Vero cells revealed the potency 
of PAMAM and TAT-PAMAM dendrimers for gene 
delivery where transfection with TAT-PAMAM 
dendrimers polyplexes resulted in significantly 
higher expression of the reporter protein and the H5 
transgene in the cells. The results showed that 
modifying the PAMAM dendrimer with TAT 
peptide can enhance cellular uptake of the DNA 
plasmid leading to higher gene expression in the 
transfected cells.  
Permeability value of DNA plasmid using 
PAMAM and TAT-conjugated PAMAM dendrimers 
was assessed through the artificial membrane, Pion 
Skin PAMPA. The PAMPA assay was aimed to 
serve as a rapid in vitro method for the evaluation of 
passive transcellular permeability. The system 
includes plates with a proprietary filter supporting an 
artificial membrane, which stimulates the skin. The 
artificial membrane immobilized on a filter is placed 
between a donor and acceptor compartments (22). 
Recent studies have described numerous tissue-
specific methods that predict the gastrointestinal 
absorption (23-26), the penetration through the 
blood–brain barrier (27-29) or the barrier function of 
human skin (30). Our results revealed that modified 
PAMAM dendrimer with TAT peptide has more 
capability in the transition of the DNA plasmid 
through the artificial membrane, as the highest 
expression of the H5 gene was observed from the 
delivery system of TAT-conjugated dendrimer 
compared to the native dendrimer. This may address 
the cellular uptake facilitation of the pDNA 
polyplexes after the insertion of the TAT peptide 
into the polymeric vector and offer it as a non-
invasive method of penetrating DNA plasmid 
through the skin.  
Several reports have demonstrated the ability of 
CPPs to enhance the transfection efficiency in vitro 
and in vivo (10). Liposomes modified with TAT 
peptide showed fast and efficient translocation into 
the cell cytoplasm with subsequent migration into 
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the perinuclear zone (31). Furthermore, a 
combination of modified HIV-1 TAT peptide and 
cationic lipids dramatically enhanced transfection 
efficiency across a range of cell lines (10). The 
mechanism of CPP function in cellular uptake and 
processing has been a matter of great controversy. 
Direct penetration via energy independent pathways 
constitutes interaction of the positively charged CPP 
with negatively charged components of the 
membrane such as heparin sulfate as well as the 
phospholipid bilayer. They involve stable or 
transient destabilization of the membrane associated 
with the folding of the peptide on the lipid 
membrane. The subsequent mechanism of 
internalization depends highly on the peptide 
concentration, peptide sequence, and lipid 
composition in each model membrane study (32). 
 
CONCLUSION 
 
This is the first study to report on the testing of 
TAT/PAMAM dendrimer system for transdermal 
delivery of DNA plasmids. Although, the overall 
results showed marginal improvement in skin 
permeation and cellular uptake of the pDNA when 
nanoparticles were formulated using TAT/PAMAM, 
the relatively low cytotoxicity and ease of 
preparation would make TAT-PAMAM dendrimer 
as a promising non-viral vector for further study 
using in vivo model. 
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